A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Choroidal Neovascularization Secondary to Pathologic Myopia
This research study is investigating a new medication called Faricimab. It's being tested for an eye problem known as choroidal neovascularization, which sometimes happens in people with severe short-sightedness (pathologic myopia). This condition can cause new, leaky blood vessels to grow behind the retina, potentially leading to vision loss. The study aims to compare Faricimab with an already approved treatment, Lucentis, to see how well it works at improving vision and whether it's safe. Participants will receive injections of either Faricimab or Lucentis into their eye, and doctors will carefully monitor their vision, eye health, and any side effects over several months.
At a glance
What is this study about?
This study is looking into a new treatment for an eye condition called choroidal neovascularization (CNV). This condition can sometimes affect people with very severe short-sightedness, known as pathologic myopia. In CNV, abnormal, new blood vessels grow under the part of the eye responsible for sharp central vision, the retina. These vessels can leak blood or fluid, causing blurred vision or vision loss. Current treatments involve injections into the eye to stop these vessels from leaking and to help preserve vision.
The main goal of this study is to compare a new medicine called Faricimab with a medicine that's already in use, called Lucentis. Both are given as injections into the eye. Researchers want to find out if Faricimab is just as good, or perhaps even better, than Lucentis at improving and maintaining vision for people with this condition. They will also be closely watching to see if Faricimab is safe and if it causes any side effects.
Taking part in a study like this helps doctors understand if new treatments are effective and safe, and it can lead to better options for patients in the future. The results will help guide treatment decisions and potentially improve the lives of many people with this particular eye problem.
Key takeaways
- This study compares a new eye treatment (Faricimab) with an existing one (Lucentis).
- It's for people with a specific eye condition linked to severe short-sightedness.
- The main goal is to see if Faricimab improves vision and is safe.
- Participation involves regular eye injections and clinic visits.
- You won't know which drug you are receiving, which is standard for research like this.
Who may be eligible?
To join this study, you need to be an adult, 18 years old or older. The study is open to both men and women.
The most important requirement is that you must have choroidal neovascularization (CNV) as a result of severe short-sightedness (pathologic myopia). This means your eye doctor will need to confirm you have this specific eye condition.
Generally, you would need to meet other health criteria, which the study team will carefully check. These would be things like your overall health, other medicines you take, and previous eye treatments, to make sure the study is right and safe for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Has your eye doctor told you that you have choroidal neovascularization?
- Is your choroidal neovascularization caused by severe short-sightedness (pathologic myopia)?
- Are you able to attend regular clinic appointments for injections and eye checks?
What does participation involve?
If you join this study, you would receive regular eye injections of either Faricimab or Lucentis. These injections are given directly into your eye. You would have frequent visits to the clinic, especially early on, where doctors would check your vision, take detailed pictures of your eye, and examine your overall eye health. This is to see how well the treatment is working and to monitor for any changes or side effects. The study involves ongoing follow-up appointments, potentially lasting up to 48 weeks (about 11 months), to track your progress and long-term safety.
Potential risks and benefits
Locations (5)
- —UnverifiedPoland
- —UnverifiedFrance
- —UnverifiedGermany
- —UnverifiedSpain
- —UnverifiedItaly
Common questions
What is choroidal neovascularization?
It's an eye condition where new, unhealthy blood vessels grow under the retina, the light-sensitive tissue at the back of your eye. These vessels can leak fluid or blood, which can blur your vision.
What is 'pathologic myopia'?
This is a term for very severe short-sightedness that can cause changes in the eye, sometimes leading to problems like choroidal neovascularization.
What's the difference between Faricimab and Lucentis?
Lucentis is an approved medicine that treats eye conditions by blocking abnormal vessel growth. Faricimab is a newer medicine being tested to see if it works similarly or better, possibly requiring fewer injections for some people.
Will I know which treatment I'm getting?
No, this is a 'double-masked' study, meaning neither you nor your doctor will know whether you are receiving Faricimab or Lucentis. This helps ensure the study results are unbiased.
How long does the study last?
The main part of the study involves following patients for up to 48 weeks, which is about 11 months, with regular check-ups and treatments.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.